CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 996 enrolled
Drug / intervention
Priorix® +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02058563
NCT02058563Phase 3Completed
CompareCT.gov

Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762)

GlaxoSmithKline·interventional·Posted Feb 10, 2014·Updated Jun 6, 2018

In Brief

A Phase 3 clinical trial evaluating Priorix® and Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine for Rubella and 2 related conditions. Completed, enrolled 996 participants across 17 sites in 3 countries.

Detailed Summary

The purpose of this study is to evaluate the immunogenicity and safety of GSK's trivalent MMR (Priorix®), comparing it to Merck"s MMR vaccine (M-M-R®II), which is approved for use in the US.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRubella, Mumps, Measles
CountriesEstonia, Slovakia, United States
CollaboratorsParexel

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 10, 2014
Enrollment StartJul 1, 2014
Primary CompletionMay 24, 2015
Study CompletionSep 17, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.4 years ago

Interventions

Priorix®biological

1 dose administered as a subcutaneous (SC) injection.

Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccinebiological

1 dose administered subcutaneously.